Opus Genetics IRD Share-Based Payment - Nonvested Awards (Number)

Share-Based Payment - Nonvested Awards (Number) at other companies

IDT CorporationIDT

18K-87.8%

Flagstar Bank FLG

2.8M-59.3%

Orange County BancorpOBT

0—

Encore Capital GroupECPG

871.1K+43.4%

KopinKOPN

6.6M+4.5%

American Battery Technology CompanyABAT

13.6M+73.6%

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's share-based payment - nonvested awards (number).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's share-based payment - nonvested awards (number)?: Opus Genetics (IRD) reported share-based payment - nonvested awards (number) of 22.9M in Q1 2026.
How has Opus Genetics's share-based payment - nonvested awards (number) changed year-over-year?: Opus Genetics's share-based payment - nonvested awards (number) decreased by 22.2% year-over-year, from 29.4M to 22.9M.